The HIV shot that could change medicine is facing its biggest test: Getting to patients
Trials show lenacapavir can all but eliminate the risk of HIV infection. Yet in the countries where it was tested, most people can't afford it.
Trials show lenacapavir can all but eliminate the risk of HIV infection. Yet in the countries where it was tested, most people can't afford it.
This article was originally published at: https://www.businessinsider.com/gilead-faces-price-debate...